Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
Daridorexant 10 mg Phase 2 Results Expected
Daridorexant 10 mg • Insomnia Disorder
Quviviq
Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
View on EMA